The U.S. Food and Drug Administration (FDA) approved a supplemental application for Ozempic (oral semaglutide) on October 17, 2025. This approval, designated NDA 213051 S-24, specifically addresses efficacy, as submitted by Novo Nordisk.
What this means
This supplemental approval for Ozempic (semaglutide) signifies that the FDA has reviewed and accepted new data related to the drug's efficacy. Supplemental applications for efficacy often involve new clinical data supporting an expanded indication, a new patient population, or a refinement of existing efficacy claims. While the specific details of the new efficacy data are not provided in this announcement, such approvals are critical steps in the lifecycle of a pharmaceutical product, potentially broadening its therapeutic application or strengthening its evidence base for current uses. This event reflects ongoing regulatory oversight and the sponsor's commitment to further defining the drug's profile.
Source
The information for this supplemental approval was sourced from the U.S. Food and Drug Administration (FDA) website. The approval, designated NDA 213051 S-24, was granted on October 17, 2025, and is publicly accessible on accessdata.fda.gov.